Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 9, 2023GenesOpen Access

Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk

View Full Paper
Ask AI
Bookmark
Share

Key result

Pharmacogenomic guidance for cardiovascular drugs shows potential to personalize therapy and improve patient care.

Why the study?

Cardiovascular diseases remain the leading cause of mortality worldwide, and advances in pharmacogenomics have enabled personalized medicine for cardiovascular pharmacotherapy.

Does a pharmacogenomic-guided approach improve the efficacy and safety of cardiovascular drugs in patients with cardiovascular diseases?

Design

Review

Authors

AMAlfredo MaurielloCardio-OncologyAAAntonia AscrizziUniversity of Campania "Luigi Vanvitelli"RMRiccardo MolinariUniversity of Campania "Luigi Vanvitelli"

Discussion

Loading...

Member takes

Implication

May support personalized CV therapy in select cases; leaves open confirmation via prospective RCTs before practice change.

Structured PICO

Does a pharmacogenomic-guided approach improve the efficacy and safety of cardiovascular drugs in patients with cardiovascular diseases?

P
Population
Patients with cardiovascular diseases, including those with coronary heart disease undergoing percutaneous coronary interventions, and those requiring anticoagulants or lipid-lowering therapies.
I
Intervention
Pharmacogenomic/genotype-guided approach for cardiovascular drugs (antiplatelets, anticoagulants, and dyslipidemia drugs).

Pharmacogenomics offers a personalized approach to cardiovascular pharmacology, potentially improving efficacy and reducing adverse effects for antiplatelets, anticoagulants, and lipid-lowering drugs.

Cite This Study

Mauriello et al. (2023) conducted a review in Cardiovascular diseases. Pharmacogenomics-guided therapy was evaluated. Pharmacogenomic-guided approaches for cardiovascular drugs, including antiplatelets, anticoagulants, and statins, show potential to personalize therapy and improve patient care.

synapsesocial.com/papers/6a0f9fbfe3460f6d4c1cd4c2https://doi.org/10.3390/genes14112057

Topics

Lipid managementCardiovascular prevention
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study2008 · 2,059 citations
  2. 2CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)2022 · 17 citations
  3. 3Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations2009 · 109 citations
  4. 4Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI2010 · 1,142 citations
  5. 5Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement2010 · 586 citations